Sleep apnea equipment and software maker ResMed to acquire Propeller Health, which helps track medication inhaler usage through sensors and an app, for $225M
Jeff Engel — [Updated 12/3/18, 3:30 pm, with CEO comments.] ResMed has inked a $225 million deal to acquire Propeller Health …
Context & Ripple Effects
ResMed spent late 2018 converting a CPAP-hardware business into a digital-health portfolio: just weeks before this deal it announced the $750M acquisition of MatrixCare, a cloud EHR for post-acute care. Propeller Health adds the other half of the chronic-respiratory stack — inhaler sensors plus an app that tracks whether patients actually take their medication.
The corpus makes the arc legible in both directions: ResMed later sold MatrixCare to Frazier for $490M, below its $750M purchase price, while consumer sleep-tracking plays like Eight Sleep kept raising at rising valuations — a useful yardstick for judging which side of ResMed's software bet held value.
First-order effects
- Propeller gives ResMed a foothold in asthma and COPD medication adherence, extending its respiratory franchise beyond sleep apnea devices into sensor-plus-app disease management.
- The $225M deal lands weeks after the MatrixCare announcement, confirming a deliberate strategy of buying recurring-revenue software rather than only selling equipment.
Second-order effects
- Inhaler-drug manufacturers gain a ready-made digital companion channel: Propeller's model turns adherence data into a service that pharma and payers can attach to respiratory therapies.
- Providers need infrastructure to actually deploy these prescribed apps, which is the gap Xealth targeted when it raised to help clinicians manage non-drug prescriptions like health apps and monitors.
Third-order effects
- Device makers rolling up chronic-disease software face a buy-and-divest cycle — ResMed's eventual MatrixCare sale at a loss shows these acquisitions don't automatically compound, and portfolio pruning follows.
- If sensor-based adherence tracking becomes standard in respiratory care, the durable asset shifts from the inhaler or CPAP unit itself to the longitudinal patient data layer built on top.
The trend: Medical device makers are assembling sensor-plus-software portfolios to manage chronic disease end-to-end, with divestitures revealing which digital-health acquisitions actually hold their price.